RPL17 and neoplasm: Secondly, PD-L1/PD-1 related immunotherapy has more side effects and only some cancer patients respond well to PD-1/PD-L1 blockade, thus a tumor vaccine with PD-L1/PD-1 immunotherapy strategy is proposed to overcome these limitations.